Bench to Bedside
IMMUNE Pharmaceuticals has established close partnerships with the Hebrew University of Jerusalem and other institutions worldwide. Our team integrates scientific excellence, drug development and commercialization experience to address unmet patient needs.
New medicines called Monoclonal Antibodies use the immune system's own defences to target specific cells and proteins involved in cancer and inflammation. They have changed physicians' therapeutic options and account now for the majority of the best selling drugs in the world.
Better understanding of the biology of severe diseases allows for selecting patients most likely to respond to targeted medicine. As a result, more patients respond to treatment with improved quality of life and lower disease–related healthcare costs.